clinical trial · NCT07521046
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Myelofibrosisropeginterferon alfa- 2bRuxolitinib
brief summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
started
May 1, 2026
primary completion
May 1, 2029
completion
May 1, 2030
last updated
Apr 17, 2026
official title
A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol